ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "auto-immunity and autoantibodies"

  • Abstract Number: 2795 • 2018 ACR/ARHP Annual Meeting

    IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus

    Huixian Hong1, Qi Wu2, PingAr Yang2, Bao Luo3, Jun Li4, Hao Li5, Daniel Cua6, Hui-Chen Hsu2 and John D. Mountz7, 1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 3DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 5Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Discovery Research, Merck Research Laboratory, Palo Alto, CA, 7University of Alabama at Birmingham, Devision of Clinical Immunology and Rheumatology; University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: IL-23 is currently a target for several forms of autoimmune diseases, yet its role in promoting pathogenic autoantibody development is less clear. IL-23 was…
  • Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting

    Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE

    Asiya Chida1, Kevin Cashman1, Scott Jenks2, Louise Hartson1, Youliang Wang1, Quan-Zhen Li Li3,4, Chandra Mohan5 and Ignacio Sanz6,7, 1Medicine, Emory University, Atlanta, GA, 2Rheumatology, Emory University School of Medicine, Atlanta, GA, 3Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 4Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, 5Biomedical Engineering, University of Houston, Houston, TX, 6Rheumatology, Emory University, Atlanta, GA, 7Medicine/Rheumatology, Emory University, Atlanta, GA

    Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
  • Abstract Number: 2526 • 2013 ACR/ARHP Annual Meeting

    An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™

    Chaim Putterman1, Irene Blanco2, Nicole Jordan3, Yves Renaudineau4, Vered Daniel Carmi5, Rachel Sorek5, Ornit Cohen-Gindi5, Miriam Lerner5, D. Scott Batty5, Idan Tamir5 and Irun R Cohen5,6, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 3Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 5ImmunArray, Rehovot, Israel, 6Immunology, Weizmann Institute of Science, Rehovot, Israel

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, recurrent, and potentially fatal multisystem inflammatory disorder mainly affecting women. SLE patients produce antibodies to many different self-antigens,…
  • Abstract Number: 1502 • 2013 ACR/ARHP Annual Meeting

    Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro

    Valerie Harris1, Biji T. Kurien2, R. Hal Scofield3, Timothy Gross4 and Mary Girton5, 1Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, 2College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: In Sjörgen’s Syndrome, an autoimmune disease, the lacrimal and salivary glands are the primarily affected glands. Previous studies have proposed autoantibodies that target type-3…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology